Acturadar.comFrance in real time

English translation in progress — this text is still shown in French.

Anti-obesity in France: reimbursement, waiting times, and parallel market

Ongoing18 events · of the 28 Oct au 10 Nov · latest fact at 11h05

View entire story

Fact 16 of 18 in the story · Sunday 8 November, 20h35

Un ancien obèse alerte sur l'effet « dévastateur » du Wegovy sur M6

Invité sur M6, Bruno Mougenot, qui a perdu 100 kilos sans médicament, met en garde contre l'effet « dévastateur » du Wegovy, qualifiant le traitement de « pansement sur une hémorragie ». L'émission revient sur les risques des traitements anti-obésité.

In brief

Health event (severity: low) nationwide, first detected on 8 November 2026 at 20:35. Reported by 1 source (1 article), last updated on 8 November 2026 at 20:35. Part of the story “Anti-obesity in France: reimbursement, waiting times, and parallel market”.

·
Category
Health
Severity
Low
Place

National

Detected
8 Nov, 20h35
Updated
8 Nov, 20h35
Reference
no.13547
01

What changed in the story at that point

02

Who is covering it, and from what angle

Method
1Uncategorised

1 article · 1 source · no rated outlet covers this topic yet (public service, agencies, official accounts…)

Story angles

This event does not yet have its own comparison: here is the story's Anti-obesity in France: reimbursement, waiting times, and parallel market.

All three sides cover the arrival of Wegovy in tablet form, but the left emphasizes industrial competition and reimbursement conditions, the center details waiting times, the parallel market, and patient testimonials, while the right highlights the non-reimbursable nature and practical information (price, side effects).

Left

Highlights the rivalry between Novo Nordisk and Eli Lilly on a rapidly growing global market, as well as the lack of reimbursement for the pills and the side effects to be aware of.

Centre

Details the concrete consequences: waiting times up to 18 months, parallel market, positioning of drug treatments versus bariatric surgery, and patient testimonials.

Right

Emphasizes the non-reimbursable nature of oral Wegovy and provides a practical format listing price, side effects, and reimbursement.

Common points

  • =Wegovy in tablet form is available in pharmacies in France starting Monday, November 2
  • =The oral version is not reimbursed
  • =Until now, Wegovy was administered by injection in France

Divergences

  • ≠The left emphasizes competition between laboratories (Novo Nordisk, Eli Lilly), an angle largely absent on the right
  • ≠The center stresses waiting times up to 18 months and the parallel market, absent from the provided left and right headlines
  • ≠The center and right detail price and side effects in a practical format, while the left favors the industrial and regulatory angle

Written by an AI from headlines and extracts only of all events in the story · 2 Nov, 03h41

03

Lire les sources · 1 article, 1 source

Publication order
  1. 20h35
    rtl.frWirevia Google Actualités France8 Nov
    "Un pansement sur une hémorragie" : sur M6, Bruno Mougenot, qui a perdu 100 kilos sans médicament, alerte sur l'effet "dévastateur" du Wegovy - RTL

    "Un pansement sur une hémorragie" : sur M6, Bruno Mougenot, qui a perdu 100 kilos sans médicament, alerte sur l'effet "dévastateur" du Wegovy RTL Ozempic, Wegovy… Derrière les promesses de perte de poids spectaculaire, quels risques pour la santé L'Humanité « Attention, ces injections ne sont pas des régimes à coups de piqûres », Jean-Baptiste Cazauran, médecin nutritionniste à propos du Wegovy et de la rétatrutide Science et vie Médicaments anti-obésité : un Français sur cinq prêt à se laisser tenter selon une enquête Ifop ladepeche.fr Obésité : deux nouvelles options de Wegovy disponibles Eg

04

Further reading